FDA approves supplement 65 for Genentech's Tecentriq
The agency cleared an efficacy supplement for the atezolizumab injection under priority review, with a status date of October 8, 2026.
The FDA approved a new supplement for Tecentriq (atezolizumab), marketed by Genentech, according to the agency's drug application database. The submission is listed as SUPPL 65 under application number BLA761034, with a submission status of AP (approved) and a submission status date of 2026-10-08.1
The supplement was processed under priority review and falls into the efficacy submission class, according to the filing record. The product covered by the application is an injectable form of atezolizumab at a strength of 1200MG/20ML, administered by injection.1
The FDA's approval letter tied to this submission is dated October 9, 2026, and is available through the agency's drug application docket. The application documents list an approval letter with a document date of 20261009.1
The record does not specify the particular indication, patient population, or clinical trial data supporting this efficacy supplement. Readers seeking those details should consult the full approval letter posted at the FDA's site for application number 761034.
Tecentriq has gone through multiple supplemental approvals since its original licensure, as reflected by the sequential numbering of this filing as the 65th supplement to the base application. No additional sponsor statements, trial results, or regulatory context beyond the database entry were included in the source record reviewed for this report.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.